Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway
Mediators of Inflammation · 2023
DOI: 10.1155/2023/3695469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, 2023. Verfasst von Ying Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shijingshan District, B…. Hauptthemen laut MEDLINE: Dexmedetomidine, Asthma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences, Peking Union Medical College.
Abstract (Originalsprache)
Asthma is a common respiratory disease characterized by chronic airway inflammation. Dexmedetomidine (DEX), a highly selective α2 adrenergic receptor agonist, has been shown to participate in regulating inflammatory states and thus exert organ protective actions. However, the potential of DEX in asthma is still unknown. This study is aimed at investigating the role of DEX in a mouse model of house dust mite- (HDM-) induced asthma and exploring its underlying mechanism. Here, we found that DEX treatment significantly ameliorated airway hyperresponsiveness, airway inflammation, and airway remodeling in the asthmatic mice, which were similar to the efficacy of the reference anti-inflammatory drug dexamethasone. In addition, DEX reversed the increased expression of toll-like receptor 4 (TLR4) and its downstream signaling adaptor molecule nuclear factor-κB (NF-κB) in the lung tissue of asthmatic mice. Furthermore, these protective effects of DEX were abolished by yohimbine, an α2 adrenergic receptor antagonist. These results indicate that DEX is capable of ameliorating airway inflammation and remodeling in asthmatic mice, and this protective effect is associated with the inhibition of the TLR4/NF-κB signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shijingshan District, Beijing, China 100144.
ORCID-Profile: Dong Yang
Förderung
- Chinese Academy of Medical Sciences
- Peking Union Medical College
Zitieren
APA
Zhou, Y., Du, X., Wang, Q., Xiao, S., Zhi, J., Gao, H., & Yang, D. (2023). Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway. Mediators of Inflammation. https://doi.org/10.1155/2023/3695469
Vancouver
Zhou Y, Du X, Wang Q, Xiao S, Zhi J, Gao H, et al. Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway. Mediators of Inflammation. 2023. doi:10.1155/2023/3695469
BibTeX
@article{Zhou2023,
author = {Zhou, Ying and Du, Xiyu and Wang, Qianyu and Xiao, Shilin and Zhi, Juan and Gao, Huibin and Yang, Dong},
title = {Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway},
journal = {Mediators of Inflammation},
year = {2023},
doi = {10.1155/2023/3695469}
}
EUVIMED